1. Home
  2. BST vs NTLA Comparison

BST vs NTLA Comparison

Compare BST & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Science and Technology Trust of Beneficial Interest

BST

BlackRock Science and Technology Trust of Beneficial Interest

HOLD

Current Price

$35.34

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$12.13

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BST
NTLA
Founded
2014
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
BST
NTLA
Price
$35.34
$12.13
Analyst Decision
Buy
Analyst Count
0
20
Target Price
N/A
$20.45
AVG Volume (30 Days)
68.2K
3.9M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
11.60%
N/A
EPS Growth
N/A
27.43
EPS
N/A
N/A
Revenue
N/A
$67,671,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$62.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.92
52 Week Low
$27.87
$5.90
52 Week High
$44.50
$28.24

Technical Indicators

Market Signals
Indicator
BST
NTLA
Relative Strength Index (RSI) 24.14 42.93
Support Level N/A $11.63
Resistance Level $41.42 $14.61
Average True Range (ATR) 0.79 0.68
MACD -0.30 -0.10
Stochastic Oscillator 2.30 4.20

Price Performance

Historical Comparison
BST
NTLA

About BST BlackRock Science and Technology Trust of Beneficial Interest

BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objective is to provide income and total return through a combination of current income, current gains, and long-term capital appreciation. It focuses on investing, under a normal market condition in equity securities of science and technology companies.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: